What is TIL's current stock price?

TIL (Instil Bio, Inc.) is currently trading at $8.18 with a market cap of $55.5M.

What sector is Instil Bio, Inc. in?

Instil Bio, Inc. (TIL) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TIL a good stock to buy?

Analysts have a Hold consensus on TIL with a price target of $7.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TIL Instil Bio, Inc.

Healthcare

$8.18+0.74%ClosedMarket Cap: $55.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.50

P/S

0.00

EV/EBITDA

-1.12

DCF Value

$-11.77

FCF Yield

-60.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-39.8%

ROA

-23.6%

ROIC

-27.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-4.2M	$—
Q4 null	$0.00	$-8.2M	$—
FY null	$0.00	$-71.4M	$—
Q3 null	$0.00	$-13.6M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$7.00

Target (Median)

$7.00

Target Range

$7.00 - $7.00

0 Strong Buy1 Buy2 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Neutral

2026-01-07

HC Wainwright & Co.Buy

2025-09-11

HC Wainwright & Co.Buy

2025-06-05

JMP SecuritiesMarket Perform

2025-06-02

Trading Activity

Insider Trades

View All

Laumas Sandeepofficer: CFO and CBO

SellFri Sep 12

Laumas Sandeepofficer: CFO and CBO

SellFri Sep 12

Laumas Sandeepofficer: CFO and CBO

SellFri Sep 12

Laumas Sandeepofficer: CFO and CBO

SellFri Sep 12

McGaughy R Kent Jrdirector

SellThu May 29

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.95

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Peers